mecasermin (Increlex, Insmed, recombinant IGF1)
Jump to navigation
Jump to search
Introduction
Tradenames: Increlex, FDA approved 2005
Indications
- FDA-approved for treating growth failure in pediatric patients with severe primary IGF-1 deficiency or growth hormone gene deletion who have developed neutralizing antibodies to growth hormone
- off label uses
- severe insulin resistance syndromes
- type A insulin resistance, Rabson-Mendenhall syndrome, Donohue's syndrome
- bypasses insulin receptor defects[4]
- growth hormone insensitivity syndrome, including Laron syndrome[3]
- severe insulin resistance syndromes
Contraindications
- not a substitute for growth hormone treatment in patients with growth hormone deficiency
Dosage
Injection: 10 mg/mL, multiple dose glass vials (40 mg/vial)
Mechanism of action
- contains human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology Manufacturers: iPlex, Insmed
More general terms
References
- ↑ Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ RxList http://www.rxlist.com/increlex-drug.htm
- ↑ 3.0 3.1 Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7. PMID: https://pubmed.ncbi.nlm.nih.gov/15860416 Review.
- ↑ 4.0 4.1 McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007 Aug;157 Suppl 1:S51-6. PMID: https://pubmed.ncbi.nlm.nih.gov/17785698 Review.